目的 觀察丹參多酚酸鹽聯(lián)合替格瑞洛治療急性冠狀動脈綜合癥的臨床療效。方法 選取鄭州市骨科醫(yī)院心內(nèi)科2016年10月-2017年9月收治的急性冠狀動脈綜合征患者106例，隨機(jī)分為對照組和治療組，每組各53例。對照組口服替格瑞洛片，首劑量180 mg/次，然后90 mg/次，2次/d；治療組在對照組基礎(chǔ)上靜脈滴注注射用丹參多酚酸鹽，200 mg加入5%葡萄糖注射液，1次/d。兩組患者均治療3周。評價兩組患者臨床療效，同時比較治療前后兩組患者心電圖改善情況、臨床癥狀改善、心功能指標(biāo)、炎癥情況、心功能和血小板功能。結(jié)果 治療后，對照組臨床有效率和心電圖有效率分別為73.58%和66.04%，均分別顯著低于治療組的92.45%和86.79%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時間均顯著減少（P<0.05）；且治療組心絞痛臨床癥狀明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者左心室舒張末期內(nèi)徑（LVEDD）、左心室收縮末期內(nèi)徑（LVESD）和左室射血分?jǐn)?shù)（LVEF）顯著升高（P<0.05）；且治療組上述心功能指標(biāo)明顯高于對照組明顯（P<0.05）。治療后，兩組患者超敏C反應(yīng)蛋白（hs-CRP）、N末端B型鈉尿肽原（NT-proBNP）和血小板聚集率（MPA）水平顯著降低（P<0.05），血小板反應(yīng)指數(shù)（PRI）顯著升高（P<0.05）；且治療組這些指標(biāo)明顯優(yōu)于對照組（P<0.05）。結(jié)論 丹參多酚酸鹽聯(lián)合替格瑞洛治療冠狀動脈綜合癥可有效改善患者炎性反應(yīng)和心臟功能，不良反應(yīng)較少，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical efficacy of salvianolate combined with ticagrelor in treatment of acute coronary syndrome. Methods Patients (106 cases) with acute coronary syndrome in Zhengzhou Orthopedics Hospital from October 2016 to September 2017 were randomly divided into control and treatment group, and each group had 53 cases. Patients in the control group were po administered with Ticagrelor Tablets, the first dose was 180 mg/time, then 90 mg/time, twice daily. Patients in the treatment group were iv administered with Salvianolate for injection on the basis of the control group, 200 mg added into 5% glucose injection, once daily. Patients in two groups were treated for 3 weeks. After treatment, the clinical efficacies were evaluated, and the improvement of ECG and clinical symptoms, the cardiac function indexes, the inflammation, heart function and platelet function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and electrocardiogram efficiency in the control group were 73.58% and 66.04%, which were significantly lower than 92.45% and 86.79% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P<0.05), and the clinical symptoms of angina pectoris in the treatment group after treatment was significantly better than that in the control group (P<0.05). After treatment, the LVEDD, LVESD and LVEF in two groups was significantly increased (P<0.05), and the cardiac function indexes in the treatment group after treatment were significantly higher than those in the control group (P<0.05). After treatment, the hs-CRP, NT-proBNP and MPA in two groups was significantly decreased (P<0.05), but PRI was significantly increased (P<0.05). And these indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). Conclusion Salvianolate combined with ticagrelor in treatment of acute coronary syndrome can effectively improve the inflammatory reaction and cardiac function with less adverse reactions, which has a certain clinical application value.